Inhibitory Immune Checkpoints Predict 7-Day, In-Hospital, and 1-Year Mortality of Internal Medicine Patients Admitted With Bacterial Sepsis

Abstract Background Sepsis is a life-threatening syndrome with complex pathophysiology and great clinical heterogeneity, which complicates the delivery of personalized therapies. Our goal was to demonstrate that some biomarkers identified as regulatory immune checkpoints in preclinical studies could...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2024-07
Main Authors: Mearelli, Filippo, Nunnari, Alessio, Rombini, Annalisa, Chitti, Federica, Spagnol, Francesca, Casarsa, Chiara, Bolzan, Giulia, Martini, Ilaria, Marinelli, Anna, Rizzo, Stefania, Teso, Cristiana, Macor, Alessandra, Fiotti, Nicola, Barbati, Giulia, Tascini, Carlo, Costantino, Venera, Di Bella, Stefano, Di Girolamo, Filippo Giorgio, Bove, Tiziana, Orso, Daniele, Berlot, Giorgio, Klompas, Michael, Biolo, Gianni
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Sepsis is a life-threatening syndrome with complex pathophysiology and great clinical heterogeneity, which complicates the delivery of personalized therapies. Our goal was to demonstrate that some biomarkers identified as regulatory immune checkpoints in preclinical studies could guide the stratification of patients with sepsis into subgroups with shared characteristics of immune response or survival outcomes. Methods We assayed the soluble counterparts of 12 biomarkers of immune response in 113 internal medicine patients with bacterial sepsis. Results IL-1 receptor-associated kinase M (IRAK-M) exhibited the highest hazard ratios (HRs) for increased 7-day (1.94; 95% confidence interval [CI], 1.17–3.20) and 30-day mortality (1.61; 95% CI, 1.14–2.28). HRs of IRAK-M and galectin-1 for predicting 1-year mortality were 1.52 (95% CI, 1.20–1.92) and 1.64 (95% CI, 1.13–2.36), respectively. Patients with elevated serum levels of IRAK-M and galectin-1 had clinical traits of immune suppression and low survival rates. Conclusions Two inhibitory immune checkpoint biomarkers (IRAK-M and galectin-1) helped identify 3 distinct sepsis phenotypes with distinct prognoses. These biomarkers shed light on the interplay between immune dysfunction and prognosis in patients with bacterial sepsis and may prove to be useful prognostic markers, therapeutic targets, and biochemical markers for targeted enrollment in therapeutic trials.
ISSN:0022-1899
1537-6613
1537-6613
DOI:10.1093/infdis/jiae370